See also this year's filing and all EDGAR filings for this company.
PDF Report 0001730430_2023_Kiniksa_Pharmaceuticals_Ltd.pdf
Logs
| warning | Large missing amount for aggregate "Expenses" added to remainder. | industry.us_generic | {'missing_ratio': 5.279451438848921, 'aggregate_val': 38070000, 'exp_sum': -8896000, 'exp_to_value': {'CostOfGoodsAndServicesSold': 0, 'SellingGeneralAndAdministrativeExpense': 97951000, 'ResearchAndDevelopmentExpense': 65490000, 'remainder_Expenses': -172337000}} |
Graph
Absolute values for 0001730430, Kiniksa Pharmaceuticals Ltd.
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 243,060,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 18,250,000 |
| 2 | PropertyPlantAndEquipmentNet | 1,658,000 |
| 3 | remainder_Assets | 196,704,000 |
| 4 | LiabilitiesCurrent | 47,066,000 |
| 5 | LiabilitiesNoncurrent | 16,457,000 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 97,951,000 |
| 9 | ResearchAndDevelopmentExpense | 65,490,000 |
| 10 | remainder_Expenses | -125,371,000 |
| 11 | remainder_Revenues | 221,433,000 |
| 12 | remainder_NetIncome | 0 |
| 13 | remainder_ComprehensiveNetIncome | 110,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 459,672,000 |
| 1 | Liabilities | 63,523,000 |
| 2 | Expenses | 38,070,000 |
| 3 | Revenues | 221,433,000 |
| 4 | StockholdersEquity | 396,149,000 |
| 5 | NetIncome | 183,363,000 |
| 6 | ComprehensiveNetIncome | 183,418,000 |
| 7 | BaseVar | 391,404,000 |
| 8 | EconomicCapitalRatio | 3.31 |
Edgar->Model Mapping
Feature Distribution
Change over Time
